Conferences - Results from #8620

#AUA15 - Debate: PCNL or URS for the 2 cm Stone - Session Highlights May 20, 2015

#AUA15 - Alkaline phosphatase velocity as a predictor of bone metastasis and overall survival in castrate resistant prostate cancer patients - Session Highlights May 20, 2015

#AUA15 - Budget impact analysis of enzalutamide for treatment of metastatic castration-resistant prostate cancer from a US payer perspective - Session Highlights May 20, 2015

#AUA15 - Patient understanding regarding end-of-life prostate cancer and perspectives regarding cost/benefit of current treatment paradigms - Session Highlights May 20, 2015

#AUA15 - Medical comorbidities, not neoadjuvant chemotherapy, affects decline in renal function following radical cystectomy and eligibility for platinum based adjuvant chemotherapy - Session Highlights May 20, 2015

#AUA15 - Neoadjuvant chemotherapy (NAC) has no adverse effect on radical cystectomy (RC) or perioperative complications - Session Highlights May 20, 2015

#AUA15 - White blood cell count at discharge following radical cystectomy associates with risk for readmission - Session Highlights May 20, 2015

#AUA15 - The severity of bowel dysfunction in patients with neurogenic bladder - Session Highlights May 19, 2015

#AUA15 - Medical complications and urological surveillance in the United States adult spina bifida population - Session Highlights May 19, 2015

#AUA15 - Crossfire: Controversies in Urology: Neuromodulation should be the first choice over botulinum toxin for idiopathic detrusor overactivity - Session Highlights May 19, 2015

#AUA15 - Role contemporary pre-cystectomy nomograms at predicting locally advanced and metastatic urothelial bladder cancer - Session Highlights May 19, 2015

Radium-223 dichloride in expanded-access setting in the United States: Overall and concurrent experience with abiraterone or enzalutamide - Session Highlights May 19, 2015

#AUA15 - Do primary hormonal therapy outcomes predict subsequent response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer? - Session Highlights May 19, 2015

#AUA15 - Best of Abstracts: Is retropubic mid-urethral sling safe and effective for patients with Valsalva voiding? - Session Highlights May 19, 2015

#AUA15 - Magnetic resonance imaging/ultrasound fusion-guided biopsy detects clinically significant prostate cancer in the central gland correlating with the index lesion - Session Highlights May 19, 2015

#AUA15 - Quality of advanced cancer care in an integrated urology/palliative care clinic - Session Highlights May 19, 2015

#AUA15 - The consequences of delaying stone treatment - Session Highlights May 19, 2015

#AUA15 - Prior bladder outflow surgery or large prostate volume does not adversely affect biochemical recurrence-free survival in low dose rate brachytherapy: An intermediate term analysis - Session Highlights May 19, 2015

#AUA15 - Risk stratification for adverse outcomes following renal mass excision - Session Highlights May 19, 2015

#AUA15 - Effect of abiraterone acetate and low dose prednisone on prostate-specific antigen in patients with non-metastatic castration-resistant prostate cancer: The results from Impact of Abiraterone Acetate in Prostate-Specific Antigen core study May 19, 2015

Page 432 of 507